Comanche Biopharma.png
Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia
January 17, 2024 06:00 ET | Comanche Biopharma
Comanche Biopharma closes oversubscribed $75 Million Series B financing to advance first treatment targeting a root cause of preeclampsia.